摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

diethyl 4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-2,9-diacetate | 193813-88-6

中文名称
——
中文别名
——
英文名称
diethyl 4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-2,9-diacetate
英文别名
ethyl 2-[4-(2-ethoxy-2-oxoethyl)-7-oxo-2,5,8-triazatetracyclo[7.7.0.02,6.010,15]hexadeca-1(9),3,5,10,12,14-hexaen-14-yl]acetate
diethyl 4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-2,9-diacetate化学式
CAS
193813-88-6
化学式
C21H21N3O5
mdl
——
分子量
395.415
InChiKey
FFFLJGWTMIDPTP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    29
  • 可旋转键数:
    8
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    99.5
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    diethyl 4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-2,9-diacetate盐酸 作用下, 以 丙酮 为溶剂, 生成 4,5dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-2,9-diacetic acid hydrochloride
    参考文献:
    名称:
    5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one derivatives,
    摘要:
    化合物的化学式(I),其中R是氢原子或--COOH,-烷基-COOH,--PO.sub.3 H.sub.2,--CH.sub.2 --PO.sub.3 H.sub.2或--CH.dbd.CH--COOH基团,或被羧基取代的苯基基团,R.sub.1是烷基-CN,-烷基-COOH,-烷基-Het,烷基-PO.sub.3 H.sub.2或-烷基-CO--NH--SO.sub.2 R.sub.2基团,R.sub.2是烷基或苯基基团,烷基是烷基基团,Het是含有1-9个碳原子和一个或多个异原子(O、S和N)的饱和或不饱和单环或多环杂环环,该杂环环可以选择性地被一个或多个烷基,苯基或苯基烷基基团取代,但是当R是氢原子或--COOH或--PO.sub.3 H.sub.2基团时,R.sub.1不能是-烷基-COOH,其同分异构体,消旋混合物,对映异构体和非对映异构体,以及其盐,其制备方法,其中间体和含有该化合物的药物已被披露。化合物的化学式(I)具有有价值的药理学性质,并且是α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)受体的拮抗剂,也被称为quisqualate受体。此外,化合物的化学式(I)是N-甲基-D-天冬氨酸(NMDA)受体的非竞争性拮抗剂,特别是NMDA受体甘氨酸调节剂位点的配体。
    公开号:
    US05990108A1
  • 作为产物:
    描述:
    参考文献:
    名称:
    Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]indeno[1,2-e]pyrazin-8- and -9-carboxylic (acetic) acid AMPA antagonists
    摘要:
    The over-stimulation of excitatory amino acid receptors such as the glutamate AMPA receptor has been suggested to be associated with neurodegenerative disorders. Here we describe an original series of readily water soluble 4-oxo-imidazo[1,2-a] indeno[1,2-e]pyrazin-8- and -9-carboxylic (acetic) acid derivatives. One of these compounds, 4f, exhibited nanomolar binding affinity, potent competitive antagonism at the ionotropic AMPA receptor and a long duration of anticonvulsant activity after administration by parenteral route in vivo. (C) 2000 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0960-894x(00)00561-8
点击查看最新优质反应信息

文献信息

  • US06100264
    申请人:——
    公开号:——
    公开(公告)日:——
  • US5990108A
    申请人:——
    公开号:US5990108A
    公开(公告)日:1999-11-23
  • US6100264A
    申请人:——
    公开号:US6100264A
    公开(公告)日:2000-08-08
  • 5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one derivatives,
    申请人:Rhone Poulenc Rorer S.A.
    公开号:US05990108A1
    公开(公告)日:1999-11-23
    Compounds of formula (I), wherein R is a hydrogen atom or a --COOH, -alk-COOH, --PO.sub.3 H.sub.2, --CH.sub.2 --PO.sub.3 H.sub.2, or --CH.dbd.CH--COOH radical, or a phenyl radical substituted by a carboxy radical, R.sub.1 is an alk-CN, -alk-COOH, -alk-Het, alk-PO.sub.3 H.sub.2 or -alk-CO--NH--SO.sub.2 R.sub.2 radical, R.sub.2 is an alkyl or phenyl radical, alk is an alkyl radical, Het is a saturated or unsaturated mono- or polycyclic heterocyclic ring containing 1-9 carbon atoms and one or more heteroatoms selected from O, S and N, said heterocyclic ring optionally being substituted by one or more alkyl, phenyl or phenylalkyl radicals, with the proviso that when R is a hydrogen atom or a --COOH or --PO.sub.3 H.sub.2 radical, R.sub.1 cannot be -alk-COOH, isomers, racemic mixtures, enantiomers and diastereoisomers thereof, salts thereof, the preparation thereof, intermediates thereof and drugs containing said compounds, are disclosed. The compounds of formula (I) have valuable pharmacological properties and are antagonists of the .alpha.-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor also known as the quisqualate receptor. Furthermore, the compounds of formula (I) are non-competitive antagonists of the N-methyl-D-aspartate (NMDA) receptor, and specifically ligands for NMDA receptor glycine modulator sites. ##STR1##
    化合物的化学式(I),其中R是氢原子或--COOH,-烷基-COOH,--PO.sub.3 H.sub.2,--CH.sub.2 --PO.sub.3 H.sub.2或--CH.dbd.CH--COOH基团,或被羧基取代的苯基基团,R.sub.1是烷基-CN,-烷基-COOH,-烷基-Het,烷基-PO.sub.3 H.sub.2或-烷基-CO--NH--SO.sub.2 R.sub.2基团,R.sub.2是烷基或苯基基团,烷基是烷基基团,Het是含有1-9个碳原子和一个或多个异原子(O、S和N)的饱和或不饱和单环或多环杂环环,该杂环环可以选择性地被一个或多个烷基,苯基或苯基烷基基团取代,但是当R是氢原子或--COOH或--PO.sub.3 H.sub.2基团时,R.sub.1不能是-烷基-COOH,其同分异构体,消旋混合物,对映异构体和非对映异构体,以及其盐,其制备方法,其中间体和含有该化合物的药物已被披露。化合物的化学式(I)具有有价值的药理学性质,并且是α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)受体的拮抗剂,也被称为quisqualate受体。此外,化合物的化学式(I)是N-甲基-D-天冬氨酸(NMDA)受体的非竞争性拮抗剂,特别是NMDA受体甘氨酸调节剂位点的配体。
  • Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]indeno[1,2-e]pyrazin-8- and -9-carboxylic (acetic) acid AMPA antagonists
    作者:Jeremy Pratt、Patrick Jimonet、Georg Andrees Bohme、Alain Boireau、Dominique Damour、Marc Williams Debono、Arielle Genevois-Borella、John C.R Randle、Yves Ribeill、Jean-Marie Stutzmann、Marc Vuilhorgne、Serge Mignani
    DOI:10.1016/s0960-894x(00)00561-8
    日期:2000.12
    The over-stimulation of excitatory amino acid receptors such as the glutamate AMPA receptor has been suggested to be associated with neurodegenerative disorders. Here we describe an original series of readily water soluble 4-oxo-imidazo[1,2-a] indeno[1,2-e]pyrazin-8- and -9-carboxylic (acetic) acid derivatives. One of these compounds, 4f, exhibited nanomolar binding affinity, potent competitive antagonism at the ionotropic AMPA receptor and a long duration of anticonvulsant activity after administration by parenteral route in vivo. (C) 2000 Elsevier Science Ltd. All rights reserved.
查看更多

同类化合物

咪唑并[1,2-a]噻吩并[3,2-E]吡嗪-5(4H)-酮 8-羟基咪唑并[1,2-a]吡嗪 5H,10H-二咪唑并[1,2-a:1,2-d]吡嗪-5,10-二酮 5H,10H-二咪唑并[1,2-a:1',5'-d]吡嗪-5,10-二酮 5,6,7,8-四氢-4H-环戊二烯并[E]咪唑并[1,2-a]吡嗪-4-酮 8-(3-benzylureido)-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one 8-(3-butylureido)-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one 8-(3-isopropylureido)-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one 2-nitroimidazo[1,2-a]pyrazin-8(7H)-one 8-(4-methylpentanoyl)amino-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one 3-(10-methyl-4,5-dihydro-4-oxo-10H-imidazo-[1,2-a]indeno[1,2-e]pyrazin-10-yl)propionitrile 10-[(1-methylimidazol-5-yl)methylene]-5H,10H-imidazo[1,2-a]indeno[1,2-e]-pyrazin-4-one hydrochloride 8-(3-tert-butylureido)-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one 8-(3-methylthioureido)-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one 10-formamido-5H,10H-imidazo[1,2-a]indeno[1,2-e]-pyrazin-4-one 10-amino-5H,10H-imidazo[1,2-a]indeno[1,2-e]-pyrazin-4-one hydrochloride 8-hydroxy-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one 8-Methoxy-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one 8-[3-morpholinoureido]-5H,10H-imidazo[1,2-a]indeno[1,2-e]-pyrazine-4-one hydrate 7-chloro-10-methylamino-5H,10H-imidazo-[1,2-a]indeno[1,2-e]pyrazin-4-one hydrochloride 7-chloro-10-formamido-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one 10-acetamido-7-chloro-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one 10-(2-pyridylmethyl)-5H,10H-imidazo[1,2-a]indeno-[1,2-e]pyrazin-4-one 10-(4-imidazolylmethyl)-5H,10H-imidazo[1,2-a]-indeno[1,2-e]pyrazin-4-one 10-(pyridin-2-ylmethylene)-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one 10-(4-imidazolylmethylene)-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one 5H,10H-8-aminoimidazo[1,2-a]indeno[1,2-e]pyrazine-4-one monohydrochloride 10-(carboxymethylene)-8-(3-methylureido)-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one 8-amino-10-(carboxymethylene)-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one dihydrochloride 8-ureido-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one [4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-8-yl]acetic acid 10-(2-methyl-1-propenyl)-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one RPR 119990 3-(9-carboxymethyl-4-oxo-5,10-dihydroimidazo[1,2-a]indeno[1,2-e]pyrazin-2-yl]propionic acid 10-[4-(imidazol-1-yl)butyl]-10-methyl-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one 12-Methyl-3-thia-1,7,10-triazatricyclo[7.3.0.02,6]dodeca-2(6),4,9,11-tetraen-8-one 3-bromo-7-methyl-imidazo[1,2-a]pyrazin-8-one 5-chloro-7-methyl-8-oxo-6-phenyl-7,8-dihydroimidazo[1,2-a]-pyrazine-3-carbaldehyde ethyl 9-(diethoxyphosphorylmethyl)-4-oxo-5,10-dihydroimidazo[1,2-a]indeno[1,2-e]pyrazine-2-carboxylate ethyl 8-fluoro-4-oxo-4,5-dihydro-10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-2-carboxylate 2-methyl-7H-imidazo[1,2-a]pyrazin-8-one 2-Methyl-7-[(1-phenylcyclopropyl)methyl]imidazo[1,2-a]pyrazin-8-one 3-bromo-2-methyl-7-(1-phenyl-cyclopropylmethyl)-7H-imidazo[1,2-a]pyrazin-8-one 5-chloro-7-(4-methoxybenzyl)-8-oxo-7,8-dihydroimidazo[1,2-a]-pyrazine-3-carbaldehyde 10-hydroxymethylene-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one 10-(carboxymethylene)-5H,10H-imidazo[1,2-a]indeno-[1,2-e]pyrazin-4-one 10-(carboxymethyl)-5H,10H-imidazo[1,2-a]indeno[1,2-e]-pyrazin-4-one 8-oxo-7,8-dihydroimidazo[1,2-a]pyrazine hydrochloride 10-amino-5H,10H-imidazo[1,2-a]indeno[1,2-e]-pyrazin-4-one 10-(4-phenylbutyramido)-5H,10H-imidazo[1,2-a]-indeno[1,2-e]pyrazin-4-one